PAM
STML

Paradigm Asset Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Paradigm Asset Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7,900
Closed -$72.7K – 551
2017
Q2 		$72.7K Sell
7,900
-8,100
-51% -$67.5K 0.01% 468
2017
Q1 		$137K Sell
16,000
-6,800
-30% -$62K 0.03% 455
2016
Q4 		$244K Sell
22,800
-700
-3% -$8.47K 0.05% 255
2016
Q3 		$255K Buy
23,500
+2,700
+13% +$22K 0.04% 304
2016
Q2 		$141K Buy
+20,800
New +$131K 0.02% 365

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paradigm Asset Management's STML Position: Q3 2017 in Review

Paradigm Asset Management sold out of Stemline Therapeutics, Inc. (STML) in Q3 2017, closing a stake of 7,900 shares — an estimated $72.7K sold.

Paradigm Asset Management first reported a position in STML in Q2 2016 and held it in 5 quarters. The position peaked at $255K in Q3 2016. 79 funds tracked by Wall St. Rank hold STML as of Q3 2017.

  • Paradigm Asset Management reported no remaining Stemline Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Paradigm Asset Management sold 7,900 Stemline Therapeutics, Inc. shares in Q3 2017, an estimated $72.7K.
  • Paradigm Asset Management first reported a position in Stemline Therapeutics, Inc. in Q2 2016 and held it in 5 quarters.
  • Paradigm Asset Management's Stemline Therapeutics, Inc. position peaked at $255K in Q3 2016.
  • 79 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2017.

Based on Paradigm Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.